FR2886855B1 - Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques - Google Patents

Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques

Info

Publication number
FR2886855B1
FR2886855B1 FR0505829A FR0505829A FR2886855B1 FR 2886855 B1 FR2886855 B1 FR 2886855B1 FR 0505829 A FR0505829 A FR 0505829A FR 0505829 A FR0505829 A FR 0505829A FR 2886855 B1 FR2886855 B1 FR 2886855B1
Authority
FR
France
Prior art keywords
biodavailability
fumagillin
derivatives
increase
macrocylic lactones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0505829A
Other languages
English (en)
Other versions
FR2886855A1 (fr
Inventor
Michel Alvinerie
Jacques Dupuy
Anne Lespine
Jean Francois Sutra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Recherche Agronomique INRA
Original Assignee
Institut National de la Recherche Agronomique INRA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0505829A priority Critical patent/FR2886855B1/fr
Application filed by Institut National de la Recherche Agronomique INRA filed Critical Institut National de la Recherche Agronomique INRA
Priority to BRPI0611642-6A priority patent/BRPI0611642A2/pt
Priority to MX2007015504A priority patent/MX2007015504A/es
Priority to AU2006256616A priority patent/AU2006256616A1/en
Priority to ZA200710600A priority patent/ZA200710600B/xx
Priority to EP06764749A priority patent/EP1888116A2/fr
Priority to US11/917,031 priority patent/US20080200402A1/en
Priority to PCT/FR2006/001297 priority patent/WO2006131649A2/fr
Priority to CA002611201A priority patent/CA2611201A1/fr
Publication of FR2886855A1 publication Critical patent/FR2886855A1/fr
Application granted granted Critical
Publication of FR2886855B1 publication Critical patent/FR2886855B1/fr
Priority to US12/975,410 priority patent/US20110144045A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0505829A 2005-06-08 2005-06-08 Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques Expired - Fee Related FR2886855B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR0505829A FR2886855B1 (fr) 2005-06-08 2005-06-08 Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
CA002611201A CA2611201A1 (fr) 2005-06-08 2006-06-08 Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocycliques
AU2006256616A AU2006256616A1 (en) 2005-06-08 2006-06-08 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones
ZA200710600A ZA200710600B (en) 2005-06-08 2006-06-08 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones
EP06764749A EP1888116A2 (fr) 2005-06-08 2006-06-08 Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocycliques
US11/917,031 US20080200402A1 (en) 2005-06-08 2006-06-08 Use Of Fumagillin And The Derivatives Thereof To Increase The Bioavilability Of The Macrocyclic Lactones
BRPI0611642-6A BRPI0611642A2 (pt) 2005-06-08 2006-06-08 utilização da fumagilina e de seus derivados para aumentar a biodisponibilidade das lactonas macrocìclicas
MX2007015504A MX2007015504A (es) 2005-06-08 2006-06-08 Uso de fumagilina y sus derivados para aumentar la biodisponibilidad de lactonas macrociclicas.
PCT/FR2006/001297 WO2006131649A2 (fr) 2005-06-08 2006-06-08 Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocycliques
US12/975,410 US20110144045A1 (en) 2005-06-08 2010-12-22 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0505829A FR2886855B1 (fr) 2005-06-08 2005-06-08 Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques

Publications (2)

Publication Number Publication Date
FR2886855A1 FR2886855A1 (fr) 2006-12-15
FR2886855B1 true FR2886855B1 (fr) 2009-07-17

Family

ID=35064492

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0505829A Expired - Fee Related FR2886855B1 (fr) 2005-06-08 2005-06-08 Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques

Country Status (9)

Country Link
US (2) US20080200402A1 (fr)
EP (1) EP1888116A2 (fr)
AU (1) AU2006256616A1 (fr)
BR (1) BRPI0611642A2 (fr)
CA (1) CA2611201A1 (fr)
FR (1) FR2886855B1 (fr)
MX (1) MX2007015504A (fr)
WO (1) WO2006131649A2 (fr)
ZA (1) ZA200710600B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865746B2 (en) * 2008-07-18 2014-10-21 Zafgen, Inc. Methods of treating an overweight or obese subject
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
WO2013055385A2 (fr) 2011-10-03 2013-04-18 Zafgen Corporation Méthodes de traitement de troubles liés à l'âge
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
MX337575B (es) 2009-10-09 2016-03-10 Zafgen Corp Compuestos de sulfona y métodos para lafabricación y uso de éstos.
BR112012016793A2 (pt) 2010-01-08 2018-07-31 Zafgen Corp compostos tipo fumagilol e métodos de fazer e usar os mesmos
WO2011085198A1 (fr) 2010-01-08 2011-07-14 Zafgen Corporation Inhibiteur de metap-2 pour utilisation dans le traitement d'une hypertrophie bénigne de la prostate (bph)
WO2011127304A2 (fr) 2010-04-07 2011-10-13 Zafgen Corporation Méthodes de traitement d'un sujet en surpoids
KR20130043207A (ko) 2010-07-22 2013-04-29 자프겐 인크. 트리시클릭 화합물 및 이의 제조 및 사용 방법
KR101892768B1 (ko) 2010-11-09 2018-08-28 자프겐 인크. Metap-2 저해제의 결정질 고체 및 그의 제조 및 이용 방법
WO2012075020A1 (fr) 2010-11-29 2012-06-07 Zafgen Corporation Traitement de l'obésité à l'aide d'une administration non quotidienne de 6 - 0 - (4 - diméthylaminoéthoxy) cinnamoyl fumagillol
MX344238B (es) 2011-01-26 2016-12-07 Zafgen Inc Compuestos de tetrazol y métodos para preparar y usar los mismos.
CN103534244B (zh) 2011-03-08 2016-10-12 扎夫根股份有限公司 氧杂螺[2.5]辛烷衍生物及类似物
EP2704709B1 (fr) 2011-05-02 2020-09-02 Altaba, Ariel Ruiz Lactones macrocycliques et leur utilisation
BR112013028534A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos tricíclicos parcialmente saturados e métodos para produção e utilização dos mesmos
AU2012253760B2 (en) 2011-05-06 2016-02-04 Zafgen, Inc. Tricyclic pyrazole sulfonamide compounds and methods of making and using same
WO2012154678A1 (fr) 2011-05-06 2012-11-15 Zafgen Corporation Composés de sulfonamide tricycliques et leurs procédés de fabrication et d'utilisation
US9440943B2 (en) 2012-01-18 2016-09-13 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
AU2013209723B2 (en) 2012-01-18 2016-11-24 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
US9260419B2 (en) 2012-05-07 2016-02-16 Zafgen, Inc. Polymorphic salt of a metap-2 inhibitor and methods of making and using same
CN104363905A (zh) 2012-05-08 2015-02-18 扎夫根股份有限公司 用metap2抑制剂治疗下丘脑性肥胖
EP2850079B1 (fr) 2012-05-09 2018-05-02 Zafgen, Inc. Dérivés de fumigillol, procédés pour leurs préparation et leurs utilisation
AU2013337282A1 (en) 2012-11-05 2015-05-21 Zafgen, Inc. Tricyclic compounds and methods of making and using same
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
MX2015005733A (es) 2012-11-05 2016-02-10 Zafgen Inc Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
SI2970101T1 (sl) 2013-03-14 2018-09-28 Alkermes Pharma Ireland Limited Prozdravila fumaratov in njihova uporaba pri zdravljenju različnih bolezni
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
EP2968250B1 (fr) 2013-03-14 2019-06-19 Zafgen, Inc. Méthodes de traitement de maladie rénale et d'autres troubles
ES2753361T3 (es) 2014-02-24 2020-04-08 Alkermes Pharma Ireland Ltd Sulfonamida y profármacos de fumaratos de sulfinamida y su uso en el tratamiento de diversas enfermedades
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5328930A (en) * 1993-03-01 1994-07-12 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin
EP0658342B1 (fr) * 1993-09-24 1999-03-17 Takeda Chemical Industries, Ltd. Composition pharmaceutique antineoplastique contenant des dérivées de fumagillol et un complex du platine
PL183378B1 (pl) * 1995-03-27 2002-06-28 Assist Publ Hopitaux De Paris Zastosowanie fumagilolu i jego pochodnych do wytwarzania jelitowych środków przeciwinfekcyjnych
CA2210600A1 (fr) * 1996-07-17 1998-01-17 Takashi Houkan Inhibiteur des metastases tumorales ou de la recurrence
CA2381829A1 (fr) * 2001-05-18 2002-11-18 Margaret Ann Smith Dordal Methode de traitement de tumeurs avec des derives du fumagillol
HUP0203718A2 (hu) * 2002-10-31 2004-08-30 Annamária Szőke Orális adagolású, állatgyógyászati hatóanyagot tartalmazó készítmény, és/vagy táplálékkiegészítő készítmény, eljárás annak előállítására és annak alkalmazása

Also Published As

Publication number Publication date
AU2006256616A1 (en) 2006-12-14
US20080200402A1 (en) 2008-08-21
WO2006131649A2 (fr) 2006-12-14
FR2886855A1 (fr) 2006-12-15
US20110144045A1 (en) 2011-06-16
CA2611201A1 (fr) 2006-12-14
MX2007015504A (es) 2008-03-18
ZA200710600B (en) 2009-05-27
EP1888116A2 (fr) 2008-02-20
WO2006131649A3 (fr) 2007-06-21
BRPI0611642A2 (pt) 2010-09-28

Similar Documents

Publication Publication Date Title
FR2886855B1 (fr) Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
FR20C1027I2 (fr) Derives de tiglien-3-one
DE502005011241D1 (de) Indazolderivate als inhibitoren der hormon-sensitiven lipase
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
BRPI0719937A2 (pt) Pró-fármacos e métodos de fazer e de usar os mesmos
CR8944A (es) Derivados de n-2 adamantanil-2-fenoxi-acetamida como inhibidores de deshidrogenasa 11-beta hidroxiesteroide
FR2862147B1 (fr) Reconfiguration dynamique de liaisons de type pci-express
CU23828B1 (es) Derivados de dihidropiridina de utilidad como inhibodires de la proteína quinasa
ZA200901714B (en) Dibenzofuran derivatives as inhibitors of pde-4 and pde-10
DK1720866T3 (da) Fremgangsmåde
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
CR10562A (es) Nuevos derivados de piridazina
BRPI0715342A2 (pt) Derivados de 6-carboxi-normorfinano, síntese e usos dos mesmos
FR2899103B1 (fr) Utilisation cosmetique de d-ribose
MA28373A1 (fr) Modulateurs furosemide de hm74
DE602004003162D1 (de) Verbesserungen in oder in Bezug auf dynamischer Bilderzeugung
DE602005015486D1 (de) Esterderivate von ascorbinsäure und 2-ketosäuresacchariden
BRPI0821921A2 (pt) Derivados de piripiropeno tendo uma atividade inibidora da acat2
DK1668324T3 (da) Businstrument med to ledninger
DK1855711T3 (da) Anvendelse af BAFF til behandling af Th2-medierede tilstande
BRPI0916532A2 (pt) nitratos de isosorbida tendo atividade vasodilatadora
MA28368A1 (fr) Modulateurs oxydecahydronaphtalene de hm74
FR2913598B1 (fr) Utilisation de derives c-glycosides pour diminuer la visibilite des pores de la peau
FR2878850B1 (fr) Derives de l'inositol-1-phosphate
UY33137A (es) (4 (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(1h-pirrolo-piridin-il)-metanonas y sintesis de las mismas

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20120229